Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed)
ID: 348066Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/348066

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-177.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Center for Advancing Translational Sciences (NCATS), is offering the Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) grant to foster innovative technology development aimed at enhancing therapeutic processes. This funding opportunity specifically targets high-risk, early-stage research projects that may lack preliminary data but show significant potential for advancements in translational science, with a focus on addressing inefficiencies in therapeutic development. The program is critical for accelerating treatment delivery across various diseases and encourages a diverse applicant pool, including institutions such as higher education, nonprofits, and small businesses. Applicants may request up to $275,000 in direct costs over a two-year project duration, with a submission deadline of June 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-177.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-177-Full-Announcement.html
    PAR-23-177.html
    The National Institutes of Health (NIH), through the National Center for Advancing Translational Sciences (NCATS), is offering funding under the 'Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS)' program, focusing on innovative technology development to enhance therapeutic processes. This R21 Exploratory/Developmental Research Grant aims to support high-risk, early-stage research projects that may lack preliminary data but display strong potential for significant advancements in the translational scientific field. Key aspects of this funding opportunity include a two-year project duration, a maximum budget of $275,000 direct costs, and a clear prohibition against clinical trials. Eligible applicants include diverse institutions such as higher education, nonprofits, local governments, and small businesses. The funding seeks applications that target inefficiencies in therapeutic development, encourage breakthrough technologies, and foster partnerships with industry. Applications must demonstrate a compelling innovation narrative and include feasibility, validation, and future plans attachments. The review process will evaluate scientific merit based on significance, innovation, approach, and investigator capabilities. The program underscores the necessity of de-risking translational science to accelerate treatment delivery for various diseases while promoting a diverse applicant pool.
    Similar Opportunities
    Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Advancing Translational Sciences (NCATS), has announced the Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) funding opportunity. This grant program aims to support early-stage, high-risk exploratory research focused on developing innovative technologies that address barriers in therapeutic development, rather than targeting specific diseases or clinical trials. The initiative is designed to expedite the discovery and delivery of treatments, diagnostics, and devices to patients by fostering innovative research that can attract industry collaboration and additional funding. Eligible applicants may request up to $275,000 in direct costs over a maximum project period of two years, with applications due by June 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the detailed announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-177.html.
    Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Center for Advancing Translational Sciences (NCATS), has announced a funding opportunity for the Limited Competition Small Grant Program (R03), aimed at supporting Clinical and Translational Science Award (CTSA) Program KL2/K12 scholars and diversity supplement recipients. This program is designed to facilitate the transition of these scholars to independent research careers by funding small, self-contained research projects that can be conducted quickly and with limited resources, ultimately addressing inefficiencies in translational science. Grants of up to $50,000 per year are available for projects lasting up to two years, with a submission deadline of January 17, 2025, and an anticipated award cycle beginning in February 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program, designated as R03 Clinical Trial Optional. This funding opportunity aims to support KL2/K12 scholars and recipients of diversity and re-entry supplements in their transition to independent research roles by funding small, innovative, self-contained projects in translational science, with a maximum budget of $50,000 per year over a two-year period. The initiative is designed to enhance the capabilities of emerging researchers in addressing inefficiencies in translating research into clinical applications, engaging underrepresented populations, and improving data accessibility through innovative technologies. Applications will be accepted starting January 19, 2024, with multiple deadlines leading up to October 20, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), aimed at supporting advanced pre-clinical research in nanotechnology-based cancer diagnostics and therapeutics. This initiative encourages innovative projects that utilize nanoparticle formulations or nano-devices to address significant clinical objectives in cancer treatment, with a focus on enhancing treatment efficacy through combination therapies and immunotherapy. Funding is available up to $475,000 annually for a maximum of four years, with applications accepted from eligible institutions including higher education entities, nonprofits, and government organizations. Interested applicants should refer to the detailed application process outlined on Grants.gov and the NIH ASSIST system, with key deadlines spanning from April 2025 to November 2027. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Limited Competition funding opportunity titled the Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3), aimed at enhancing translational research through collaborative efforts among multiple medical research institutions. This initiative seeks to support the development, implementation, and dissemination of innovative solutions that address urgent public health needs and promote health equity, requiring applicants to include at least three eligible organizations to foster interdisciplinary partnerships. Eligible projects can receive funding of up to $650,000 annually for a total duration of up to five years, with applications due by October 19, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-296.html.
    Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards." This initiative aims to support the development and demonstration of innovative resources and capabilities within Clinical and Translational Science Awards (CTSA) Program hubs, specifically targeting critical gaps and roadblocks in clinical research. Successful applicants, who must be active UM1 CTSA award recipients, will propose projects lasting up to five years with an annual budget cap of $500,000, emphasizing collaboration and innovation in health research. Interested parties should note that the application deadline is September 14, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment" funding opportunity (FOA PAR-21-166). This initiative aims to foster collaborations between academic institutions and industry to translate scientific discoveries into practical diagnostic and therapeutic solutions, specifically targeting the development of methods or tools for disease prevention, diagnosis, and treatment. The program is particularly significant as it seeks to bridge gaps in healthcare technology and enhance the effectiveness of disease management across various settings, while explicitly excluding clinical trials. Eligible applicants can receive funding up to $499,000 per year for a maximum of five years, with applications due by January 8, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the funding announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-21-166.html.
    Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Limited Competition Funding Opportunity titled "High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards." This initiative aims to support the development of unique capabilities and resources to address critical gaps in clinical and translational science within awarded UM1 Clinical and Translational Science Awards (CTSA) Program Hubs. The funding opportunity, numbered PAR-25-156, allows for project budgets of up to $500,000 per year over a project period of up to five years, with applications involving clinical trials being optional. Interested applicants, primarily from public and state-controlled institutions of higher education, must submit detailed integration plans, milestones, and sustainability evaluations by the closing date of September 28, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled “Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed),” aimed at supporting exploratory research for innovative biomedical technologies. This initiative focuses on high-risk projects that have not yet established feasibility, specifically targeting the development of tools such as laboratory instruments, algorithms, and chemical reagents, while excluding applications that address specific biological questions or present existing proof of concept data. Eligible applicants can request funding of up to $275,000 over two years, with a maximum of $200,000 in any single year, and applications are due by May 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-126.html.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the CCRP Initiative for Countermeasures Against Chemical Threats (CounterACT), aimed at supporting translational exploratory/developmental research projects that advance novel medical countermeasures (MCMs) for serious health impacts resulting from acute exposure to toxic chemical threats. The initiative specifically seeks projects that develop or repurpose existing FDA-approved products as potential treatments, generating preliminary data necessary for broader NIH support, while excluding basic research or environmental decontamination technologies. This funding opportunity has a ceiling of $275,000 over a two-year period, with applications due by May 30, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.